In summary, elevated IL-10 and TGF-β1 levels in gastric cancer synergistically enhance immune checkpoint gene expression, including CD274 and CTLA4, thereby strengthening the immunosuppressive microenvironment and informing immune therapy resistance mechanisms and combined targeted strategies. The gene discussed is IL10; the disease is gastric cancer.